Compare TransMedics Group Inc (TMDX) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs TORM plc — how do they compare? TransMedics Group Inc trades at $79.01 (market cap $2.74B), while TORM plc trades at $40.01 (market cap $4.12B). The key difference: TORM plc is the larger of the two by market cap, and TORM plc pays a 11.03% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and TORM plc for 23 Days on average.
| TMDX | TRMD | |
|---|---|---|
Market Cap | $2.74B | $4.12B |
Volume | 949,331 | 2,863,116 |
Sector | Health | Industrials |
52-Week High | $150.42 | $41.05 |
52-Week Low | $61.99 | $19.39 |
Typical Hold Time | 24 Days | 23 Days |
Enterprise Value | $3.13B | $4.83B |
Dividend Yield | — | 11.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TMDX trades at $81.07, up 0.98% today, but faces a bearish technical signal with recent price weakness. Fundamentally, the company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying and ongoing legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 consensus target, supported by a 69% buy rating from analysts, but risks include earnings misses, margin pressure from heavy investment, and legal overhangs. Execution on growth amid rising costs remains critical for sustaining its premium valuation.
TRMD trades at $38.92, down 0.33% on the day, with strong technical momentum showing a bullish moving average signal despite RSI_6 indicating potential overbought conditions. Fundamentally, the company demonstrates robust profitability with 35.52% net income margin and attractive valuation metrics including a 6.59 P/E ratio. Recent earnings showed mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates.
The outlook remains positive with 100% analyst buy ratings and improving cash flow projections for 2026. Key risks include spot rate volatility in the tanker market and recent insider selling activity. The stock offers value characteristics with strong dividend potential but faces near-term headwinds from declining contracted rates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
